Overview
Bronchitol is a dry powder mucociliary clearance agent for patients with cystic fibrosis (CF), delivered through a small hand-held inhaler with capsules containing mannitol.
- Indication
- For the treatment of CF in paediatric and adult populations six years and above, as an add-on therapy to dornase alfa, or in patients intolerant to or inadequately responsive to dornase alfa
- Reimbursement
- PBS listed
- Made in Australia
- Developed and manufactured in Australia since 2011
- Manufacturer
- Pharmaxis Ltd, Frenchs Forest, Sydney
- Distributor in Australia
- BTC Speciality Health Pty Ltd
Bronchitol in Australia
Bronchitol (inhaled mannitol) is approved in Australia. All enquiries, requests for information and reports of adverse events from Australia should be directed to BTC Speciality Health Pty Ltd.
Order codes
| Factory Code | Australia Order Code | NZ Order Code | Description |
|---|---|---|---|
| 400070 | CH2 2599045 | N/a | BRONCHITOL Initiation Dose, Assessment (BIDA) Pack (free of charge - training tool) |
| 400084 | CH2 2599037 | N/a | BRONCHITOL® (mannitol) PBS Pack, 1 x 14-day pack (280 capsules + 2 inhaler devices) - MOQ 4 packs |
Ordering and support
How to order
- Phone
- 1300 720 274
- Fax
- 1300 364 008
- hospital@ch2.net.au
- Hours
- 8am to 6pm AEST, 8am to 5pm WA time
Medical information and adverse events
- Phone
- 1800 100 282 or +61 404 869 472
BTC Speciality Health Pty Ltd, Level 1, 10 Oxley Road, Hawthorn VIC 3122.
